Cargando…
PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Autores principales: | Mohammed, Turab, Shahzad, Moazzam, Peres, Lauren, Khadka, Sushmita, Colinleitzinger, Christelle, Babu, Abida, Doyle, William, Puglianini, Omar Castaneda, Oswald, Laura, De Avila, Gabe, Grajales-Cruz, Ariel, Blue, Brandon, Ochoa-Bayona, Jose, Smith, Eric, Corallo, Salvatore, Khimani4, Farhad, Faramand, Rawan, Elmariah, Hany, Lazaryan, Aleksandr, Jain, Michael, Liu, Hien, Nishihori, Taiga, Shain, Ken, Baz, Rachid, Alsina, Melissa, Locke, Frederick, Freeman, Ciara, Hansen, Doris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429647/ http://dx.doi.org/10.1097/01.HS9.0000975160.46377.e2 |
Ejemplares similares
-
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023) -
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study
por: Lee, Dae Hyun, et al.
Publicado: (2023) -
Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
por: Ionescu, Filip, et al.
Publicado: (2022) -
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
por: Logue, Jennifer M., et al.
Publicado: (2022) -
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
por: Lazaryan, Aleksandr, et al.
Publicado: (2022)